Last updated on June 2020

Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer

Brief description of study

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer

Detailed Study Description

This is a first-in-human study of AZD9833 monotherapy (Parts A and B) and AZD9833 in combination with palbociclib (Parts C and D) in women with ER Positive HER2 Negative advanced breast cancer that is not amenable to treatment with curative intent. Parts A and C of the study allow for an escalation of AZD9833 dose alone (Part A) or in combination with palbociclib (Part C). In Parts B and D of the study, eligible subjects will be randomised to receive selected doses of AZD9833 alone (Part B) or in combination with palbociclib (Part D).

Clinical Study Identifier: NCT03616587

Find a site near you

Start Over

Research Site

Sarasota, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.